Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial

United Therapeutics receives FDA clearance to advance inhaled PAH therapy into clinical trials

US WorldMeds acquires Orbus Therapeutics

DifGen Pharmaceuticals completes European Decentralised Procedure for Tafamidis 61 mg Capsules

Astellas and Audax Biosciences sign exclusive option and licence agreement for DAX-044

Lynk Pharmaceuticals reports positive Phase III trial results for zemprocitinib in rheumatoid arthritis

IRLAB Therapeutics receives US patent allowance for Parkinson's drug candidate IRL1117

Thor Medical signs three-year isotope supply agreement with Medicines Discovery Catapult

Enhertu wins EU approval for HER2-positive early breast cancer treatment

Riboscience reports Phase 1a/b overall survival data for ENPP1 inhibitor RBS2418

Cumberland Pharmaceuticals to submit New Drug Application for ifetroban

Innovent Biologics' sintilimab new indication application accepted for review by NMPA

Genmab reports 28.2-month median overall survival with petosemtamab combination in Phase 2 trial

Akeso presents Phase III HARMONi-GI1 trial results in biliary tract cancer at ESMO 2026

Sichuan Kelun-Biotech announces Phase III OptiTROP-Lung04 study results at 2026 ESMO